colony stimulating factor 3

Quizartinib, also know as AC220 and AC010220, is an orally available FLT3 STK1 inhibitor with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3 STK1), colony-stimulating factor 1 receptor (CSF1R FMS), stem cell factor receptor (SCFR KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.

Linifanib (AL-39324) 是一种高效口服的VEGFR 和PDGFR 家族多靶点抑制剂，具有显著的抗肿瘤活性。它对无关 RTKs、可溶性酪氨酸激酶或丝氨酸 苏氨酸激酶的活性要低得多。它是特异性 miR-10b 抑制剂，阻断miR-10b 的生物合成。

AZ683是一种高效的选择性3-氨基-4-苯胺喹啉结构的CSF1R抑制剂,对CSF1R展现出较强的亲和力(Ki=8 nM; IC50=6 nM).此外,AZ683具有良好的口服生物利用度.[11C]AZ683可用作正电子发射断层扫描(PET)中的集落刺激因子1受体(CSF1R)示踪剂.

Dovitinib 是一种口服有效的、多靶点的酪氨酸激酶 (RTK) 抑制剂，具有抗肿瘤作用。